Study explored the relationship between SARS-CoV-2 infection in children under two years old and cognitive development, finding no evidence of increased developmental delays post-infection. Differences in socioeconomic status were noted between COVID-19 positive and negative groups.
By Tarun Sai LomteReviewed by Benedette Cuffari, M.Sc.Oct 15 2024 While toddlers seem resilient to COVID-19, this new study highlights how socioeconomic factors, not the virus, may play a larger role in developmental outcomes.
Simultaneously, the incidence of coronavirus disease 2019 and post-COVID-19 conditions has increased, particularly among adults and adolescents. Cognitive difficulties are widespread among individuals with long-COVID, even those who experienced mild symptoms during the infection. Children who were diagnosed with COVID-19 before February 2022, as well as those with epilepsy or documented developmental delays, were excluded from the analysis. The Thai version of the Ages and Stages Questionnaire -3 was administered during scheduled health checks.
Study findings High Symptom Prevalence: Nearly 97% of children in the COVID-19 group exhibited symptoms, with fever present in over 94% and upper respiratory tract infections common, yet no cases of pneumonia were detected.
SARS SARS-Cov-2 Adolescents Children Coronavirus Covid-19 Fever Omicron Research Respiratory Severe Acute Respiratory Severe Acute Respiratory Syndrome Syndrome
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New study links persistent SARS-CoV-2 proteins to long COVID symptomsBrigham researchers found people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood, compared to those without long COVID symptoms.
Read more »
Study identifies wildlife species likely involved in the origin of SARS-CoV-2A new international study provides a shortlist of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019.
Read more »
Antiviral-resistant variants of SARS-CoV-2 can emerge in immunocompromised peopleIndividuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH)...
Read more »
Drug-resistant SARS-CoV-2 variants found in immunocompromised patientsIndividuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH)...
Read more »
Antiviral drug molnupiravir linked to new mutations in SARS-CoV-2Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown.
Read more »
Two studies find SARS-CoV-2 virus becoming resistant to antiviral drugs used to treat patientsTwo studies have found that the virus that causes COVID-19 is becoming resistant to two drugs used to treat patients with infections.
Read more »